Nektar Therapeutics (NKTR) 11.21 $NKTR
Technical Summary on Pharma Stocks -- Research on Salix Pharma, Nektar Therapeutics, Corcept Therapeutics, and Jazz Pharma
PR Newswire - Mon May 12, 11:30AM CDT
The US markets saw a positive sentiment on Friday, May 9, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session 0.20% higher at 16,583.34, and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The gains were broad based as six out of the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, with the index advancing 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd (NASDAQ: SLXP), Nektar Therapeutics (NASDAQ: NKTR), Corcept Therapeutics Inc. (NASDAQ: CORT) and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free technical research on SLXP, NKTR, CORT and JAZZ can be downloaded upon signing up at:
Here's What You Need to Know About Nektar Therapeutics' Upcoming Catalysts
George Budwell, The Motley Fool - Motley Fool - Sun May 11, 8:16AM CDT
Regulatory and clinical catalysts are the lifeblood of developmental-stage biotechs in many ways. And as we've seen multiple times this year, these types of catalysts can catapult biotech stocks higher or cause them to crash with lightning speed. ...
Wider-than-Expected Q1 Loss at Nektar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 10:20AM CDT
Nektar (NKTR) reported a loss of 37 cents per share in the first quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 35 cents.
Nektar Therapeutics Reports Financial Results for the First Quarter of 2014
PR Newswire - Wed May 07, 3:15PM CDT
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2014.
Allergic Rhinitis Therapeutics Pipeline Review 2014 - Analysis of 35 Companies & 54 Drug Profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zkn5w5/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Genentech, Inc. - Nektar Therapeutics - BioTech Tools - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - ALK-Abello A/S - Mitsubishi Tanabe Pharma Corporation - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Revance Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Array BioPharma Inc. - Stallergenes S.A. - Cytos Biotechnology AG - Allergopharma Joachim Ganzer KG - Respiratorius AB - AnaptysBio, Inc. - Oxagen Limited - Axikin Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. - Laboratorios LETI S.L. - Celsus Therapeutics Plc - KAEL-GemVax Co., Ltd. - GlycoMar Limited - Fountain Biopharma Inc. - Ampio Pharmaceuticals, Inc. - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/zk...c_rhinitis
Nektar to Announce Financial Results for the First Quarter 2014 on Wednesday, May 7, 2014, After Close of U.S.-Based Financial Markets
PR Newswire - Thu May 01, 3:10PM CDT
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2014 on Wednesday, May 7, 2014, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).
Global Pheochromocytoma Global Clinical Trials Review 2014 - Espy the Top 15 Companies/Institutions
M2 - Wed Apr 30, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mvv7qm/pheochromocytoma) has announced the addition of the "Pheochromocytoma Global Clinical Trials Review, H1, 2014" report to their offering. Pheochromocytoma Global Clinical Trials Review, H1, 2014" provides data on the Pheochromocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pheochromocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pheochromocytoma. Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Progenics Pharmaceuticals, Inc. - Nektar Therapeutics - Jubilant Life Sciences Limited - Insys Therapeutics, Inc. - GE Healthcare - National Cancer Institute - University of California, San Francisco - Seoul National University Hospital - Assistance Publique Hopitaux De Marseille - Cincinnati Children's Hospital Medical Center - European Organization for Research and Treatment of Cancer - University Medical Center Groningen - University of Southern California - Rouen University Hospital - University Hospital, Angers For more information visit http://www.researchandmarkets.com/research/mv...romocytoma
Global Kidney Disease Therapeutics Pipeline Review 2014 - Analysis of 22 Companies & 32 Drug Profiles
M2 - Mon Apr 28, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ls4c8m/kidney_disease) has announced the addition of the "Kidney Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Kidney Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Kidney Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - Nektar Therapeutics - Chugai Pharmaceutical Co., Ltd. - LEO Pharma A/S - Teva Pharmaceutical Industries Limited - Zydus Cadila Healthcare Limited - Gentium S.p.A. - Celldex Therapeutics, Inc. - Osteologix Holdings Plc. - Ahn-Gook Pharmaceutical Co., Ltd. - DiaMedica Inc. - Upsher-Smith Laboratories, Inc. - TetraLogic Pharmaceuticals - ChemoCentryx, Inc. - Anexon, Inc. - Otsuka Holdings Co., Ltd. - BIOPROJET SCR - Advicenne Pharma - ZS Pharma, Inc. - G1 Therapeutics, Inc. - AbbVie Inc. Drug Profiles - ADV-7809 - benazepril hydrochloride - ADV-7103 - tolvaptan - methylprednisolone - ZS-9 - AGNPN-803 - hydrocodone bitartrate ER - LEO-27847 - DM-199 - tiprolisant - CCX-872 - RG-7641 - CDX-1189 - CU-NP - Necrostatin Program - Oligotide - NKTR-228 - CCR2 Antagonist - CH-5451098 - SkQR-1 - TNT-009 - SLR-080811 Derivative - AVE-0991 - NBS-101 - Prod-1 - messenger RNA Therapeutics Program - AHRO-200 - CDK-4/6 Inhibitors As Renal Protectants - A77-Based Monobody For more information visit http://www.researchandmarkets.com/research/ls...ey_disease
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
Why Nektar Therapeutics (NKTR) Stock Is Up Today
at The Street - Tue Apr 22, 2:51PM CDT
Nektar Therapeutics (NKTR) stock continues to climb following a 'buy' rating by analysts at Jefferies (JEF)
Nektar Presents Pipeline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:10PM CDT
Nektar presented preclinical data on NKTR-102 and NKTR-214 at the AACR.
Watch List for Equities Hitting New High -- Research on Nektar Therapeutics, Clean Diesel Technologies, MeetMe, and Bazaarvoice
PR Newswire - Thu Apr 10, 12:06PM CDT
The US markets finished on a positive note on Wednesday, April 09, 2014, with the NASDAQ Composite closing at 4,183.90, up 1.72%, the Dow Jones Industrial Average ending the session at 16,437.18, up 1.11%, and the S&P 500 gained 1.09% to finish the trading session at 1,872.18. The gains were broad based as eight out of ten sectors finished on a positive note. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Nektar Therapeutics (NASDAQ: NKTR), Clean Diesel Technologies Inc. (NASDAQ: CDTI), MeetMe Inc. (NYSE: MEET) and Bazaarvoice Inc. (NASDAQ: BV). Free technical research on NKTR, CDTI, MEET and BV can be downloaded upon signing up at:
MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO
at The Street - Thu Apr 10, 10:52AM CDT
Dance Biopharma is developing a device which sends vaporized insulin liquid into a patient's lungs.
Nektar Reports Positive Preclinical Data for Two Oncology Programs at 2014 AACR
PR Newswire - Wed Apr 09, 8:00AM CDT
Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technologies, today announced that preclinical data for NKTR-102 and NKTR-214 were presented at the 2014 Annual Meeting of the American Association of Cancer Research (AACR) being held in San Diego, California.
Nektar Rises on FDA Notification (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 1:50PM CDT
If approved, naloxegol would be the first once-daily oral treatment for patients with chronic OIC.
Uptrend Call Working As Nektar Therapeutics Stock Rises 21.0% (NKTR)
Comtex SmarTrend(R) - Thu Mar 20, 9:21AM CDT
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 4 months, Nektar Therapeutics has returned 20.96% as of today's recent price of $14.31.
Nektar Rises on FDA Notification - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 5:16PM CDT
Nektar's shares gained more than 9% on Mar 18.
Nektar Therapeutics Has Returned 12.9% Since SmarTrend Recommendation (NKTR)
Comtex SmarTrend(R) - Wed Mar 12, 5:19PM CDT
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 4 months, Nektar Therapeutics has returned 12.93% as of today's recent price of $13.36.
Patient Support Programs, Financial Results, and Stock Price Movements - Analyst Notes on Gilead, Forest Laboratories, Thermo Fisher Scientific, HCA Holdings, and Nektar
PR Newswire - Thu Mar 06, 7:25AM CST
Editor Note: For more information about this release, please scroll to bottom.
Technical Summary on Pharma Stocks -- Research on Salix Pharma, Nektar Therapeutics, Corcept Therapeutics, and Jazz Pharma
PR Newswire - Mon May 12, 11:30AM CDT
The US markets saw a positive sentiment on Friday, May 9, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session 0.20% higher at 16,583.34, and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The gains were broad based as six out of the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, with the index advancing 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd (NASDAQ: SLXP), Nektar Therapeutics (NASDAQ: NKTR), Corcept Therapeutics Inc. (NASDAQ: CORT) and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free technical research on SLXP, NKTR, CORT and JAZZ can be downloaded upon signing up at:
Here's What You Need to Know About Nektar Therapeutics' Upcoming Catalysts
George Budwell, The Motley Fool - Motley Fool - Sun May 11, 8:16AM CDT
Regulatory and clinical catalysts are the lifeblood of developmental-stage biotechs in many ways. And as we've seen multiple times this year, these types of catalysts can catapult biotech stocks higher or cause them to crash with lightning speed. ...
Wider-than-Expected Q1 Loss at Nektar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 10:20AM CDT
Nektar (NKTR) reported a loss of 37 cents per share in the first quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 35 cents.
Nektar Therapeutics Reports Financial Results for the First Quarter of 2014
PR Newswire - Wed May 07, 3:15PM CDT
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2014.
Allergic Rhinitis Therapeutics Pipeline Review 2014 - Analysis of 35 Companies & 54 Drug Profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zkn5w5/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Genentech, Inc. - Nektar Therapeutics - BioTech Tools - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - ALK-Abello A/S - Mitsubishi Tanabe Pharma Corporation - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Revance Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Array BioPharma Inc. - Stallergenes S.A. - Cytos Biotechnology AG - Allergopharma Joachim Ganzer KG - Respiratorius AB - AnaptysBio, Inc. - Oxagen Limited - Axikin Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. - Laboratorios LETI S.L. - Celsus Therapeutics Plc - KAEL-GemVax Co., Ltd. - GlycoMar Limited - Fountain Biopharma Inc. - Ampio Pharmaceuticals, Inc. - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/zk...c_rhinitis
Nektar to Announce Financial Results for the First Quarter 2014 on Wednesday, May 7, 2014, After Close of U.S.-Based Financial Markets
PR Newswire - Thu May 01, 3:10PM CDT
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2014 on Wednesday, May 7, 2014, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).
Global Pheochromocytoma Global Clinical Trials Review 2014 - Espy the Top 15 Companies/Institutions
M2 - Wed Apr 30, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mvv7qm/pheochromocytoma) has announced the addition of the "Pheochromocytoma Global Clinical Trials Review, H1, 2014" report to their offering. Pheochromocytoma Global Clinical Trials Review, H1, 2014" provides data on the Pheochromocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pheochromocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pheochromocytoma. Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Progenics Pharmaceuticals, Inc. - Nektar Therapeutics - Jubilant Life Sciences Limited - Insys Therapeutics, Inc. - GE Healthcare - National Cancer Institute - University of California, San Francisco - Seoul National University Hospital - Assistance Publique Hopitaux De Marseille - Cincinnati Children's Hospital Medical Center - European Organization for Research and Treatment of Cancer - University Medical Center Groningen - University of Southern California - Rouen University Hospital - University Hospital, Angers For more information visit http://www.researchandmarkets.com/research/mv...romocytoma
Global Kidney Disease Therapeutics Pipeline Review 2014 - Analysis of 22 Companies & 32 Drug Profiles
M2 - Mon Apr 28, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ls4c8m/kidney_disease) has announced the addition of the "Kidney Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Kidney Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Kidney Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - Nektar Therapeutics - Chugai Pharmaceutical Co., Ltd. - LEO Pharma A/S - Teva Pharmaceutical Industries Limited - Zydus Cadila Healthcare Limited - Gentium S.p.A. - Celldex Therapeutics, Inc. - Osteologix Holdings Plc. - Ahn-Gook Pharmaceutical Co., Ltd. - DiaMedica Inc. - Upsher-Smith Laboratories, Inc. - TetraLogic Pharmaceuticals - ChemoCentryx, Inc. - Anexon, Inc. - Otsuka Holdings Co., Ltd. - BIOPROJET SCR - Advicenne Pharma - ZS Pharma, Inc. - G1 Therapeutics, Inc. - AbbVie Inc. Drug Profiles - ADV-7809 - benazepril hydrochloride - ADV-7103 - tolvaptan - methylprednisolone - ZS-9 - AGNPN-803 - hydrocodone bitartrate ER - LEO-27847 - DM-199 - tiprolisant - CCX-872 - RG-7641 - CDX-1189 - CU-NP - Necrostatin Program - Oligotide - NKTR-228 - CCR2 Antagonist - CH-5451098 - SkQR-1 - TNT-009 - SLR-080811 Derivative - AVE-0991 - NBS-101 - Prod-1 - messenger RNA Therapeutics Program - AHRO-200 - CDK-4/6 Inhibitors As Renal Protectants - A77-Based Monobody For more information visit http://www.researchandmarkets.com/research/ls...ey_disease
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
Why Nektar Therapeutics (NKTR) Stock Is Up Today
at The Street - Tue Apr 22, 2:51PM CDT
Nektar Therapeutics (NKTR) stock continues to climb following a 'buy' rating by analysts at Jefferies (JEF)
Nektar Presents Pipeline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:10PM CDT
Nektar presented preclinical data on NKTR-102 and NKTR-214 at the AACR.
Watch List for Equities Hitting New High -- Research on Nektar Therapeutics, Clean Diesel Technologies, MeetMe, and Bazaarvoice
PR Newswire - Thu Apr 10, 12:06PM CDT
The US markets finished on a positive note on Wednesday, April 09, 2014, with the NASDAQ Composite closing at 4,183.90, up 1.72%, the Dow Jones Industrial Average ending the session at 16,437.18, up 1.11%, and the S&P 500 gained 1.09% to finish the trading session at 1,872.18. The gains were broad based as eight out of ten sectors finished on a positive note. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Nektar Therapeutics (NASDAQ: NKTR), Clean Diesel Technologies Inc. (NASDAQ: CDTI), MeetMe Inc. (NYSE: MEET) and Bazaarvoice Inc. (NASDAQ: BV). Free technical research on NKTR, CDTI, MEET and BV can be downloaded upon signing up at:
MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO
at The Street - Thu Apr 10, 10:52AM CDT
Dance Biopharma is developing a device which sends vaporized insulin liquid into a patient's lungs.
Nektar Reports Positive Preclinical Data for Two Oncology Programs at 2014 AACR
PR Newswire - Wed Apr 09, 8:00AM CDT
Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technologies, today announced that preclinical data for NKTR-102 and NKTR-214 were presented at the 2014 Annual Meeting of the American Association of Cancer Research (AACR) being held in San Diego, California.
Nektar Rises on FDA Notification (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 1:50PM CDT
If approved, naloxegol would be the first once-daily oral treatment for patients with chronic OIC.
Uptrend Call Working As Nektar Therapeutics Stock Rises 21.0% (NKTR)
Comtex SmarTrend(R) - Thu Mar 20, 9:21AM CDT
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 4 months, Nektar Therapeutics has returned 20.96% as of today's recent price of $14.31.
Nektar Rises on FDA Notification - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 5:16PM CDT
Nektar's shares gained more than 9% on Mar 18.
Nektar Therapeutics Has Returned 12.9% Since SmarTrend Recommendation (NKTR)
Comtex SmarTrend(R) - Wed Mar 12, 5:19PM CDT
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 4 months, Nektar Therapeutics has returned 12.93% as of today's recent price of $13.36.
Patient Support Programs, Financial Results, and Stock Price Movements - Analyst Notes on Gilead, Forest Laboratories, Thermo Fisher Scientific, HCA Holdings, and Nektar
PR Newswire - Thu Mar 06, 7:25AM CST
Editor Note: For more information about this release, please scroll to bottom.
